<DOC>
	<DOCNO>NCT00539331</DOCNO>
	<brief_summary>The National Cancer Institute Canada Clinical Trials Group ( NCIC-CTG ) inform AstraZeneca BR24 Phase II/III study cediranib 30mg first line non-small cell lung cancer ( NSCLC ) continue Phase III follow planned end Phase II efficacy tolerability analysis study 's Data Safety Monitoring Committee . Although evidence clinical activity see , appear imbalance toxicity therefore study consider meet pre-defined criterion automatic continuation Phase III . As design Study 040 similar Study BR24 , AstraZeneca suspend recruitment Study 040 .</brief_summary>
	<brief_title>Phase I/II Study AZD2171 Combination With Paclitaxel/Carboplatin Japanese Non-Small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Having histologically cytologically confirm NSCLC Patients previously untreated advanced/metastatic ( Stage IIIB/IV ) postsurgery recurrent NSCLC WHO performance status 01 Untreated unstable brain meningeal metastases Patient inappropriate laboratory test value Patient poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>AZD2171</keyword>
	<keyword>Paclitaxel/Carboplatin</keyword>
	<keyword>Non-small Cell Lung Cancer ( NSCLC )</keyword>
</DOC>